PatrĂ­cia Silva, PhD, director of science content —

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

SteadyMed’s Treyvent Awarded Orphan Drug Designation from FDA

SteadyMed, Ltd., a company that develops products to treat orphan and high-value conditions with unmet parenteral delivery needs, recently announced that its lead product candidate, Trevyent® has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).

Tackling New Zealand Alps to Promote PH Awareness, Research

Team PHenomenal Hope will take part in a seven-day cycling competition to raise awareness of pulmonary hypertension (PH) and money to advance research into the disease. The nonprofit, presented by the University of Pittsburgh Medical Center (UPMC), Bayer Healthcare, and Actelion, is competing in the The Pioneer race through New Zealand’s Southern Alps.

Top 10 Most Read Pulmonary Hypertension Articles of 2015

Pulmonary Hypertension News has covered news surrounding the latest treatments, events, clinical trials, and research updates related to pulmonary hypertension on a daily basis throughout the past year. As the year of 2015 comes to an end, our “Top 10 Most Read Pulmonary Hypertension Articles of 2015” ranks the…

Systemic Sclerosis and Lung Fibrosis Study of Nintedanib Enrolls First Patient

Boehringer Ingelheim recently announced the enrollment of the first patient in its global, double-blind, randomized, and placebo-controlled SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) Phase 3 clinical trial. The trial (NCT02597933) is now enrolling patients, and is evaluating the safety and the efficacy of nintedanib in patients with systemic sclerosis (SSc)…

Pulmonary Hypertension Researchers Win 2015 Deutscher Zukunftspreis

German President Joachim Gauck has awarded the 2015 Deutscher Zukunftspreis, which honors innovation in science and technology, to a pulmonary hypertension (PH) research team that discovered and developed a drug effective in the treatment of two serious types of the disease. The winning team — led by Professor Ardeschir Ghofrani from the University Clinic…

Eiger BioPharmaceuticals’ PAH Therapy Bestatinâ„¢ (Ubenimex) Receives Notice of Allowance for U.S. Patent

Eiger BioPharmaceuticals, Inc. recently announced in a press release that a Notice of Allowance from the United States Patent and Trademark Office (USPTO) has been issued for the U.S. patent application 13/829,321, titled “Treatment of Pulmonary Hypertension with Leukotriene Inhibitors” covering Bestatinâ„¢ (ubenimex), a leukotriene A4hydrolase (LTA4H) inhibitor, for treating…

PHA’s Sacramento Santa Run Promises Another Fun Fundraiser

The Sacramento Santa Run, now in its third year, is holding a 5k Run/Walk and a Merry Mile event on Saturday, Dec. 19, to benefit the California Chapter of the Pulmonary Hypertension Association (PHA). The full-day charity event opens at 7 a.m. with race registration and the run/walk itself, beginning at the State…

PHA Welcomes Scholarship Applicants for Its 2016 Conference

The Pulmonary Hypertension Association’s International PH Conference and Scientific Sessions is one of the largest gatherings on pulmonary hypertension (PH) worldwide, bringing patients, caregivers and top healthcare professionals together to share stories, exchange information, and network. Planning for the 2016 conference, to take place in Dallas, Texas, from June 17-19, is getting underway, and…

PHA Celebrates PH Awareness Month with Major Campaign

November is Pulmonary Hypertension Awareness Month and the Pulmonary Hypertension Association (PHA) is planning to launch a new public service campaign called Heart2CurePH that promises to increase understanding of pulmonary hypertension (PH). The worldwide educational campaign will include TV, radio, and place-based and print materials, while anyone on social media can…

Pulmonary Hypertension Gets New Treatment in Helpful Comic Book

The latest comic book in a peer-reviewed series on pulmonary hypertension (PH) has been launched by Medikis, with the collaboration of the Imperial College Healthcare NHS Trust. The comic book, entitled Medikidz Explains Pulmonary Arterial Hypertension, aims to increase knowledge about the life-threatening disease among younger audiences.


A Conversation With Rare Disease Advocates